Axotret

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Axotret

What is Axotret?

Axotret is a pharmaceutical medication containing the active substance isotretinoin. It belongs to a group of medicines known as retinoids, which are derivatives of Vitamin A. This medication is primarily used for the treatment of severe forms of acne that have not responded adequately to standard treatments, such as systemic antibiotics and topical therapies.

Mechanism of Action

The active ingredient, isotretinoin, works by addressing the various biological factors that contribute to the development of acne. Its primary functions include:

  • Reduction of Sebum Production: It significantly decreases the activity and size of the sebaceous glands, which reduces the amount of oil (sebum) produced by the skin.
  • Inhibition of Follicular Keratinization: It helps prevent the clogging of pores by normalizing the process of skin cell shedding within the hair follicles.
  • Anti-inflammatory Properties: It exerts an anti-inflammatory effect on the skin, helping to reduce the redness and swelling associated with severe acne lesions.
  • Bacterial Suppression: By altering the skin environment and reducing sebum, it indirectly reduces the proliferation of Cutibacterium acnes, the bacteria often associated with acne inflammation.

Clinical Application

Axotret is typically reserved for cases of acne that are likely to cause permanent scarring or significant psychological distress. These conditions include nodular acne, acne conglobata, or acne that is at high risk of leaving indelible marks. Because it treats the condition systemically, it affects the skin across the entire body, making it an option for patients with extensive involvement on the face, chest, and back.

What side effects are possible with Axotret?

Possible Side Effects and Safety Information

The safety profile for Axotret (isotretinoin) is comprehensively classified by regulatory authorities (such as the FDA and EMA) based on the frequency and system-organ class affected. This section describes the formally documented adverse reactions and safety constraints.

Frequency-Classified Adverse Reactions

Adverse reactions classified as very common (affecting more than 1 in 10 people) primarily involve mucocutaneous and musculoskeletal systems, including cheilitis (lip inflammation), dryness of the skin and mucosa, dry eyes, back pain, and arthralgia (joint pain). Biochemical changes such as elevated triglycerides and liver transaminases are also documented as very common or common (affecting up to 1 in 10 people) and require monitoring throughout the treatment course.

Adverse effects classified as rare (affecting up to 1 in 1,000 people) include depressed mood, aggressive behavior, and suicidal ideation. Very rare documented effects (affecting up to 1 in 10,000 people) include the development of Inflammatory Bowel Disease (IBD), Pseudotumor Cerebri (Benign Intracranial Hypertension), and serious dermatological reactions like Stevens-Johnson Syndrome (SJS).

Critical Safety Constraints

The use of Axotret carries an absolute contraindication in pregnancy due to the extremely high risk of severe, life-threatening birth defects (teratogenicity). Furthermore, the drug is contraindicated in individuals with pre-existing hepatic impairment and severely elevated blood lipid levels. These high-level constraints formally define the strict boundaries for the medicine's regulatory use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Axotret (isotretinoin) overdose emphasizes both the general acute effects and specific, high-risk scenarios, strictly defined by government health authorities.

Documented Acute Manifestations

Acute overdose may result in symptoms consistent with Hypervitaminosis A, which are generally documented as mild and expected to be reversible. Manifestations may include:

  • Vomiting
  • Facial flushing
  • Headache
  • Dizziness
  • Abdominal pain

Critical Risk and Emergency Action

While the physical symptoms are usually self-limiting, the single most critical concern in an overdose situation is exposure during pregnancy. Isotretinoin is a severe human teratogen; therefore, overdose in a patient who is or may become pregnant presents a catastrophic, non-reversible risk of major fetal malformations.

Management is symptomatic and supportive, as no specific antidote is known. However, immediate medical attention is required:

  • Immediate contact with a Poison Control Center or Emergency Room is mandatory following any suspected overdose.
  • If overdose or exposure is suspected in a patient who is pregnant, the drug must be discontinued immediately, and the patient must seek urgent medical evaluation and counseling.

Therapeutic Uses of Axotret

What Axotret Treats: Main Uses and Benefits

Axotret (isotretinoin) is a highly specialized systemic retinoid used in situations involving the intensive management of severe, chronic acne. Its therapeutic focus supports the goal of achieving sustained skin clearance in patients whose condition may be resistant to standard courses of treatment.

The medication is used for severe, recalcitrant nodular acne that has not been helped by other treatments.

Severe, Recalcitrant Nodular and Cystic Acne

Axotret is applied in the dermatological context to treat severe, nodular, and cystic forms of acne that may be categorized as recalcitrant—meaning they have failed to respond adequately to extensive prior therapy, including systemic antibiotics. This treatment targets the symptom clusters characterized by deep, painful inflammatory lesions and widespread pustules, and may assist with managing the severity of damaging manifestations of the condition.

Prevention of Permanent Scarring

The treatment is commonly used to help with managing the long-term physical consequence of severe disease: permanent scarring. The overall therapeutic goal supports the goal of achieving sustained symptom control, which contributes to easing the significant psychosocial burden associated with chronic, highly visible skin damage.


Quick Fact: Supports Management of Scarring Risk

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Axotret (Isotretinoin)

Official regulatory information defines strict population criteria for using Axotret. The medication is absolutely contraindicated in several populations and is subject to restrictive use for others.

Populations for Whom Use is Prohibited

Axotret is contraindicated and must not be used by pregnant females or nursing women due to the extremely high risk of severe birth defects (teratogenicity) and potential adverse effects on the infant. It is also prohibited for patients with a known hypersensitivity to isotretinoin, hepatic insufficiency (impaired liver function), or pre-existing hypervitaminosis A (excessive vitamin A levels).

Age and Restricted Use

Axotret is approved for use in patients 12 years of age and older. Use is not recommended for children under 12 years of age or for the treatment of prepubertal acne. Females of childbearing potential are eligible only if they fully comply with all required conditions of a mandatory risk management program, including routine negative pregnancy tests and the use of two forms of reliable contraception. Patients with severe renal insufficiency require initiation at a lower starting dose.

Comorbidity Limitations

Use is contraindicated for patients concurrently taking tetracycline antibiotics. Furthermore, individuals with diabetes, obesity, or a history of lipid metabolism disorder require especially careful evaluation and monitoring by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Axotret (isotretinoin) is defined by mandated prohibitions against co-administration with other substances that cause additive systemic toxicity and a required administration condition that affects its systemic exposure.

Contraindicated Combinations

Official regulatory documentation classifies the following combinations as strictly contraindicated due to the risk of severe, additive adverse effects:

  • Tetracycline Antibiotics: Co-administration is prohibited due to the heightened, additive risk of pseudotumor cerebri (benign intracranial hypertension).
  • Vitamin A Supplements: Use with supplements containing Vitamin A is prohibited, as Axotret is a retinoid, and combining them increases the risk of additive adverse reactions characteristic of hypervitaminosis A.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Administration with a meal is a mandatory condition because this pharmacokinetic interaction significantly increases the drug's systemic exposure (AUC and Cmax), which is necessary for achieving required therapeutic levels. Other substances listed in regulatory documents include phenytoin and systemic corticosteroids. Additionally, St. John's wort is a concern as it may reduce the efficacy of hormonal contraceptives, which are a required co-therapy for females of childbearing potential, as mandated by the risk management program.

Mechanism of Action

Axotret (Isotretinoin) works by engaging a multi-step biological mechanism that fundamentally alters the skin's physiology at the cellular level through sustained modulation of gene expression.

Nuclear Receptor Modulation and Transcriptional Programming

The drug's active form functions as an agonist for specific nuclear receptors, mainly the Retinoic Acid Receptors ( RARs), which are abundant in sebocytes. This binding initiates transcriptional modulation, where the receptor complex alters the genetic programming of these cells. This mechanism involves the control of the synthesis rate of key proteins that regulate the sebaceous gland's survival and function.


Sebocyte Apoptosis and Gland Involution

The altered gene expression triggers a direct signal for programmed cell death (apoptosis) specifically in the sebocytes, a process mediated by upregulated transcription factors like FoxO. This mechanism leads to the involution and shrinkage of the entire sebaceous gland structure. The resulting physiological effect is a sustained hyposebogenesis (reduction in oil production), which decreases the availability of the lipid-rich environment required by C. acnes.


Modulation of Follicular Differentiation

The drug's action extends to modulating the process of follicular keratinization—the way skin cells grow and shed within the hair follicle. This mechanism alters the dynamics of cell adhesion and shedding, influencing the material composition within the follicular canal. Coupled with its anti-inflammatory modulation of immune responses, this action combines the sebostatic, differentiation, and inflammatory pathways in the overall mechanism.

Dosage and Administration Information

Axotret (isotretinoin) is an intensive therapy administered orally in capsule form. The dosage regimen is highly individualized and determined based on the patient's body weight and their disease response. The typical daily dose range is 0.5 to 1.0 mg/kg per day. The total daily amount is typically administered in two divided doses (BID) to maintain therapeutic levels.

To ensure proper absorption, Axotret capsules should generally be taken with a meal and must be swallowed whole with a full glass of liquid to prevent esophageal irritation. The treatment course is not defined by a fixed time but by achieving a total cumulative dose of 120 to 150 mg/kg, which is correlated with long-term remission. A standard course typically lasts 15 to 20 weeks.

For specific populations, patients with severe renal impairment should start treatment at a lower dose (e.g., 10 mg/day). The standard weight-based dosing applies to non-pregnant patients 12 years of age and older. If a dose is missed, the standard procedure is to skip the missed dose and resume the normal schedule, with no dose doubling permitted. A second course of Axotret must not be started until at least two months after the first course has concluded, allowing time for potential continued improvement.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Axotret (Isotretinoin)

This overview summarizes the research evidence and clinical evaluation studies conducted on Axotret (isotretinoin), focusing on the types of evidence that governmental and scientific bodies rely on to understand its role. It describes what research examined and what remains uncertain.


Evidence for Use in Severe, Recalcitrant Nodular and Cystic Acne

The primary research base for Axotret consists of Randomized Controlled Trials (RCTs) and Systematic Reviews, which research examined in patients with severe acne. Studies focused on individuals, mainly adolescents (12 years and older) and young adults, whose severe cystic or nodular acne had already failed to respond adequately to multiple other treatments, including systemic antibiotics.

Researchers examined how symptoms evolved by monitoring the frequency and size of inflammatory lesions, such as nodules and cysts. The trials measured the changes in these lesion counts and monitored the proportion of participants who met specific, pre-defined criteria for skin clearance by the end of the treatment period, which typically lasted 15 to 20 weeks. Studies report how symptoms evolved in the observed populations, with findings describing patterns related to the measured clearance criteria by the end of the defined time interval. Research contributes to the broader evidence landscape for conditions characterized by fluctuating or episodic manifestations.


Long-Term Studies and Follow-up Evidence

Research has also explored the long-term status of patients after they completed the standard course of Axotret. Studies monitored participants over defined time intervals extending beyond the treatment phase, typically lasting up to 12 months post-treatment, with some observational settings evaluating daily-life functioning for 18 months to 3 years or more.

The primary long-term outcomes studied were related to the duration of symptom stability and the rate of recurrence (relapse). These observational studies reported how symptoms evolved in the observed populations, where data show patterns related to observed symptom evolution that continued for a large portion of participants. Findings, however, also describe patterns of relapse in others.

A key limitation here is that long-term effects are not fully established through extended, multi-year randomized controlled trials. Instead, the data on the durability of the response relies more heavily on less rigorous designs like observational studies. For this reason, certainty remains low when projecting outcomes far beyond the initial follow-up periods reported in the core trials.

Key Studies & References

  1. Clinical Overview: Isotretinoin (Absorica) for Severe Recalcitrant Nodular Acne
  2. Acne Relapse and Isotretinoin Retrial in Patients With Acne (2025 Study)
  3. Acne Recurrence after Treatment with Oral Isotretinoin: 5-year follow-up
  4. Acne Relapse Rate and Predictors of Relapse Following Treatment with Oral Isotretinoin
  5. High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne Vulgaris

Frequently Asked Questions (FAQ)

Common questions about Axotret (FAQ)

Q: What kind of general safety monitoring or tests are typically involved during Axotret use?

Official guidance states that regular monitoring and testing are required during use. This typically involves baseline and ongoing blood tests to check liver function and blood lipid levels, such as triglycerides and cholesterol. For patients who can become pregnant, monthly negative pregnancy tests are also mandatory to comply with safety program requirements.

Q: Are there specific dietary changes that are often discussed in relation to taking Axotret?

To ensure the medication is properly absorbed, official documents state that Axotret capsules must be taken with a meal. Beyond this required administration condition, high alcohol consumption is officially listed as a risk factor because it can cause additive effects, leading to a rise in blood lipid levels that requires monitoring.

Q: What are the regulations around how Axotret is prescribed?

Due to the severe risk of birth defects (teratogenicity), Axotret is distributed through a mandatory restricted distribution program established by regulatory authorities. This program requires the patient, the prescriber, and the pharmacy to all be enrolled and to comply with specific, ongoing safety requirements.

Q: Do people who use Axotret need to change their daily activities?

Official patient information indicates certain activities require caution during and immediately after treatment. Patients must not donate blood while taking the drug or for one month after stopping. Furthermore, official information advises against skin-smoothing procedures, such as waxing, dermabrasion, and laser treatments, due to the increased risk of scarring.

Q: What type of medical professional typically prescribes Axotret?

The medication is only allowed to be prescribed by physicians who are enrolled and activated in the required restricted distribution safety program. Because Axotret is a powerful systemic medicine, official guidance indicates it is typically prescribed by specialist providers, such as dermatologists.

Q: Does Axotret make a person's skin more vulnerable to sun damage?

Yes, official warnings state that Axotret can cause photosensitivity. This means the skin becomes more vulnerable to damage from sun exposure, sunlamps, and tanning beds. Taking this medication increases the risk of severe sunburn.

Q: Are there any known issues combining Axotret with common over-the-counter pain relievers?

Regulatory documents list some common over-the-counter medications as potential concerns due to the way they are processed in the body. Specifically, common pain relievers containing acetaminophen (or Paracetamol) are mentioned because, like Axotret, they are broken down by the liver, potentially increasing the risk of liver strain.

Q: Do the common side effects associated with Axotret usually stop once the treatment is finished?

According to patient medication guides, official information indicates that many of the very common adverse reactions are temporary. Side effects primarily affecting the skin and mucosa, such as dryness of the skin, chapped lips, and dry eyes, typically resolve after the course of treatment is completed.

Q: Does Axotret interact with consumption of alcohol or caffeine?

Official warnings strongly discourage the consumption of alcohol while taking this medication. Regulatory documents cite an increased risk of elevated triglyceride levels and additional strain on the liver when Axotret and alcohol are used concurrently. Information regarding caffeine is not explicitly highlighted as a specific interaction concern.

Q: Can men who plan to conceive a child take Axotret?

Official prescribing information and studies specifically address the safety profile for men. Research in male patients has shown that Axotret has no measurable effect on sperm quality, count, or function. The level of the drug found in semen is extremely low, and official information indicates this level is not likely to pose a risk to the fetus during conception.

Q: Is it common to feel very tired when starting Axotret?

Official adverse reaction information indicates that unusual tiredness or low energy is a symptom that requires monitoring. While it is not classified as one of the most common reactions, fatigue can be associated with a severe but rare adverse effect, such as muscle damage, and official guidance states this symptom requires prompt reporting to a healthcare provider.

Q: What should a person generally know about managing dryness while taking Axotret?

Official patient information provides non-directive general tips for managing the very common side effect of dryness. General management strategies listed in official patient information include the regular use of moisturizers, lip balm, and lubricating eye drops. Petroleum jelly may also be used inside the nose to help relieve internal dryness.

How should Axotret be stored and disposed of?

Storage and Disposal Requirements

Axotret (isotretinoin) must be stored and handled according to official regulatory guidelines to maintain its stability and prevent unauthorized exposure.

Storage Conditions

Axotret capsules must be stored at room temperature, generally between 20 C and 25 C (68 F and 77 F) [Source 2.7]. It must be protected from excessive heat, moisture, and direct light, and must not be frozen [Source 2.2]. The medication should be kept in its closed container or original package and stored out of the reach of children [Source 2.2, 3.2]. Never share this medicine with another person [Source 2.2].

Disposal Instructions

Due to its potential risk, the official instruction is to return all unused capsules to the pharmacist at the end of treatment [Source 3.2]. Additionally, individuals must not donate blood while taking Axotret and for one month after stopping the medication [Source 2.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Axotret found in:

A-Z Index: